Ewing Sarcoma - Pipeline Review, Q3 2011

Description: Ewing Sarcoma - Pipeline Review, Q3 2011

Summary

Global Markets Direct's, 'Ewing Sarcoma - Pipeline Review, Q3 2011', provides an overview of the Ewing Sarcoma therapeutic pipeline. This report provides information on the therapeutic development for Ewing Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ewing Sarcoma. 'Ewing Sarcoma - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ewing Sarcoma.
- A review of the Ewing Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ewing Sarcoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Ewing Sarcoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ewing Sarcoma Overview
Therapeutics Development
An Overview of Pipeline Products for Ewing Sarcoma
Ewing Sarcoma Therapeutics under Development by Companies
Ewing Sarcoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Ewing Sarcoma Therapeutics - Products under Development by Companies
Ewing Sarcoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Ewing Sarcoma Therapeutics Development
Genzyme Corporation
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
ImClone Systems Incorporated
Oncolytics Biotech Inc.
Jennerex Biotherapeutics, Inc.
PharmaMar, S.A.
Ewing Sarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
IMC-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JX-594 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Reolysin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCH 717454 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zalypsis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bivastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLG201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Exatecan Mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Torisel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Ifosfamide + Vincristine sulfate +
Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Doxorubicin + Ifosfamide + Cyclophosphamide + Etoposide + Busulfan + Melfalan + Peripheral Stem Cells Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Celecoxib + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Vinblastine + Vincristine Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mozobil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Busulfan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Gemcitabine + Filgrastim/Pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Yondelis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Treosulfan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoledronic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiotepa + Melphalan + Allogeneic Hematopoietic Stem Cell Transplantion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ewing Sarcoma Therapeutics – Drug Profile Updates
Ewing Sarcoma Therapeutics - Discontinued Products
Ewing Sarcoma - Featured News
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Ewing Sarcoma, Q3 2011
Products under Development for Ewing Sarcoma – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Genzyme Corporation, 2011
Daiichi Sankyo Company, Ltd, 2011
Merck & Co., Inc., 2011
ImClone Systems Incorporated, 2011
Oncolytics Biotech Inc., 2011
Jennerex Biotherapeutics, Inc., 2011
PharmaMar, S.A., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Ewing Sarcoma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Ewing Sarcoma, Q3 2011
Products under Development for Ewing Sarcoma – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1863298/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Ewing Sarcoma - Pipeline Review, Q3 2011
Web Address: http://www.researchandmarkets.com/reports/1863298/
Office Code: SCD23HjX

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr □] [Mrs □] [Dr □] [Miss □] [Ms □] [Prof □]
First Name: .................................................. Last Name: ..................................................
Email Address: * ..................................................
Job Title: ................................................................
Organisation: ......................................................
Address: ................................................................
City: ....................................................................
Postal / Zip Code: ..................................................
Country: ..................................................................
Phone Number: ....................................................
Fax Number: .......................................................  

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083310383
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World